Merz Therapeutics North America

NEWS

Merz Therapeutics to present robust data on XEOMIN® (incobotulinumtoxinA) at Toxins 2022 Conference in New Orleans, LA

Merz Therapeutics announced today the presentation of data from 10 accepted abstracts on XEOMIN® (incobotulinumtoxinA) at TOXINS 2022

November 7, 2023

10 min read

Merz Therapeutics donates $100,000 to support construction of new rehabilitation center at University of North Carolina

Merz Therapeutics announced today its U.S. organization has made a $100,000 donation to the University of North Carolina (UNC) Health Foundation

November 7, 2023

2 min read

Merz Therapeutics to present key data on XEOMIN® (incobotulinumtoxinA) at Toxins 2021 Virtual Conference

18 accepted abstract presentations provide important updates and data on XEOMIN. Abstracts also published in Toxicon, a peer-reviewed interdisciplinary journal on toxins

November 7, 2023

11 min read

IN THE PRESS

Job Trends

Merz Enters Asset Purchase Agreement With a US-Based Biotech Company

April 2, 2024

3 min read

Deals

Acorda Therapeutics and Merz Announce Signing of “Stalking Horse” Asset Purchase Agreement

April 1, 2024

8 min read

FDA

FDA Approves Pediatric Indication for XEOMIN® (incobotulinumtoxinA) for the Treatment of Chronic Sialorrhea

December 21, 2020

11 min read

AWARDS

JOBS